Alaunos Therapeutics, Inc.
NASDAQ:TCRT
2.02 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Alaunos Therapeutics, Inc. |
Symbool | TCRT |
Munteenheid | USD |
Prijs | 2.02 |
Beurswaarde | 3,234,525 |
Dividendpercentage | 0% |
52-weken bereik | 2 - 33 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Kevin S. Boyle Sr. |
Website | https://www.alaunos.com |
An error occurred while fetching data.
Over Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)